Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...

If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects ...

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...

Pfizer’s PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January. Image Source: Zacks ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer's stock has declined 40% over the past three years, as it has struggled to attract investors. Investors appear to be underrating its growth prospects, as the company has a robust pipeline. Its ...

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Pfizer beat on 2025 sales and beat on earnings -- but still delivered a loss. Pfizer reaffirmed 2026 sales and earnings guidance for under $3 per share. 10 stocks we like better than Pfizer › Pfizer ...

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks Consensus Estimate of 57 cents per share. Earnings rose 5% year over year.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, ...